(Print or Type Responses)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPR	OVAL
OMB Number:	3235-0287
Estimated average b	urden
hours per response	0.5

longer subject to Section 16. Form 4 or Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Form 5 obligations may Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * RODRIGUEZ RAUL R					2. Issuer Name and Ticker or Trading Symbol RIGEL PHARMACEUTICALS INC [RIGL]						5. R	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner					
(Eirst) (Middle) RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD.					3. Date of Earliest Transaction (Month/Day/Year) 03/30/2009						X	X_ Officer (give title below) Other (specify below) EVP, COO					
(Street)				4. If A	4. If Amendment, Date Original Filed(Month/Day/Year)						_X_1	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person					
SOUTH	SAN FRA	NCISCO, CA 94	4080									onn med by we	re man one rep	Jording 1 Crson			
(Ci	ty)	(State)	(Zip)				Tal	ole I - No	n-Deriv	ative Securities	Acquired,	Disposed of	, or Benefic	ially Owned			
1.Title of S (Instr. 3)	Security		2. Transaction Date (Month/Day/Ye				Coc (Ins	ransaction de str. 8)	(A)	Securities Acqui) or Disposed of str. 3, 4 and 5)	(D) Own Tran	5. Amount of Securities Beneficia Owned Following Reported Fransaction(s)		O Fe	wnership of B	7. Nature of Indirect Beneficial	
			(M	Month/Day/Year)			Code	V An	(A) or (D)	(Inst	(Instr. 3 and 4)		oı (I	Indirect (I	Ownership Instr. 4)		
Reminder:	Report on a s	separate line for each	h class of securities b	II - Der	ivati	ive Securiti	es A	Pe th cu	ersons is form irrently	who respond are not requi valid OMB co	red to respontrol num	oond unles ber.			SEC 14	74 (9-02)	
1. Title of Derivative Security (Instr. 3)	Conversion	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code	tion	5. Number	Expiration Date (Month/Day/Year) S d of		7. Title an of Underly Securities (Instr. 3 an	ring	8. Price of Derivative Security (Instr. 5)	Derivative Securities Beneficially Owned Following Reported Transaction(s	Form of Derivativ Security: Direct (D or Indirect (I)	(Instr. 4)			
				Code	v	(A)	(D)	Date Exercisa	ible	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4)		
Stock Option (Right to Buy)	\$ 6.49	03/30/2009		A		115,000		04/30/	2009 <mark>(1</mark>	03/30/2019	Commo	115,000	\$ 0	115,000	D		

Reporting Owners

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
RODRIGUEZ RAUL R RIGEL PHARMACEUTICALS, INC. 1180 VETERANS BLVD. SOUTH SAN FRANCISCO, CA 94080			EVP, COO				

Signatures

/s/ Dolly Vance (Attorney-in-Fact)	03/31/2009
**Signature of Reporting Person	Date

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C.
- (1) The shares vest monthly over one (1) year from the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.